Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence

References

• Pradaxa [package insert]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals Inc2015
   Google Scholar
• Xarelto [package insert]Titusville, NJJanssen Pharmaceuticals Inc2016
   Google Scholar
• Eliquis [package insert]Princeton NJBristol-Myers Squibb2016
   Google Scholar
• Savaysa [package insert]Parsippany, NJDaiichi Sankyo Inc2015
   Google Scholar
• GoASFangMCUdaltsovaNImpact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) studyCirculation2009119101363136919255343
   PubMed Web of Science ®Google Scholar
• StangierJRathgenKStähleHMazurDInfluence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre studyClin Pharmacokinet201049425926820214409
   PubMed Web of Science ®Google Scholar
• LehrTHaertterSLiesenfeldKHDabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulationJ Clin Pharmacol20125291373137821956604
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMMueckWEffects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitorBr J Clin Pharmacol201070570371221039764
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• EINSTEIN InvestigatorsOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med2010363262499251021128814
   PubMed Web of Science ®Google Scholar
• ConnollySJEikelboomJJoynerCApixaban in patients with atrial fibrillationN Engl J Med2011364980681721309657
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• HohnloserSHHijaziZThomasLEfficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trialEur Heart J201233222821283022933567
   PubMed Web of Science ®Google Scholar
• Hokusai VTE InvestigatorsEdoxaban versus warfarin for the treatment of symptomatic venous thromboembolismN Engl J Med2013369151406141523991658
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• HijaziZHohnloserSHOldgrenJEfficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (randomized evaluation of long-term anticoagulation therapy) trial analysisCirculation2014129996197024323795
   PubMed Web of Science ®Google Scholar
• BöhmMEzekowitzMDConnollySJChanges in renal function in patients with atrial fibrillation: an analysis from the RE-LY trialJ Am Coll Cardiol201565232481249326065986
   PubMed Web of Science ®Google Scholar
• FountzilasCGeorgeJLevineRDabigatran overdose secondary to acute kidney injury and amiodarone useN Z Med J20131261370110112
   PubMedGoogle Scholar
• KernanLItoSShiraziFBoesenKFatal gastrointestinal hemorrhage after a single dose of dabigatranClin Toxicol (Phila)201250757157322800505
   PubMed Web of Science ®Google Scholar
• MaddryJKAmirMKSessionsDHeardKFatal dabigatran toxicity secondary to acute renal failureAm J Emerg Med2013312462.e1e2
   PubMed Web of Science ®Google Scholar
• MarinoKKSantiagoRADewRB3rdManagement of dabigatran-associated bleeding with two doses of idarucizumab plus hemodialysisPharmacotherapy20163610e160e16527581709
   PubMed Web of Science ®Google Scholar
• ShafiSTNegreteHRoyPJuliusCJSaracEA case of dabigatran-associated acute renal failureWMJ2013112417317624734407
   PubMedGoogle Scholar
• StöllbergerCLindnerKFinstererJGastrointestinal bleeding under dabigatranJ Postgrad Med201460219219324823522
   PubMed Web of Science ®Google Scholar
• WychowskiMKKouidesPADabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairmentAnn Pharmacother2012464e1022496474
   PubMedGoogle Scholar
• SamamaCMRosencherNKleineEObservational study of dabigatran etexilate 150 mg in patients with moderate renal impairment undergoing elective total hip or knee replacementThromb Res201614310311027208980
   PubMed Web of Science ®Google Scholar
• TurpieAGHaasSKreutzRA non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustmentThromb Haemost201411119410224154549
   PubMed Web of Science ®Google Scholar
• FordyceCBHellkampASLokhnyginaYOn-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AFCirculation20161341374727358435
   PubMed Web of Science ®Google Scholar
• HoriMMatsumotoMTanahashiNRivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to ageCirc J20147861349135624705469
   PubMed Web of Science ®Google Scholar
• SuzukiMFukamizuSOyamaJRationale and design of the efficacy of rivaroxaban on renal function in patients with non-valvular atrial fibrillation and chronic kidney disease: the X-NOAC studyInt J Cardiol2015188525325889327
   PubMed Web of Science ®Google Scholar
• StöllbergerCFinstererJRivaroxaban 10 mg/d in severe renal failure does not prevent ischemic events in premorbid neurologic diseaseNeurol Neurochir Pol201549318018226048606
   PubMed Web of Science ®Google Scholar
• KufelWDZayacASLehmannDFMillerCDClinical application and pharmacodynamic monitoring of apixaban in a patient with end-stage renal disease requiring chronic hemodialysisPharmacotherapy20163611e166e17127643979
   PubMed Web of Science ®Google Scholar
• EikelboomJWConnollySJGaoPStroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney diseaseJ Stroke Cerebrovasc Dis201221642943522818021
   PubMed Web of Science ®Google Scholar
• KoretsuneYYamashitaTKimuraTFukuzawaMAbeKYasakaMShort-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairmentCirc J20157971486149525925842
   PubMed Web of Science ®Google Scholar
• ColemanCILimoneBSobierajDMDosing frequency and medication adherence in chronic diseaseJ Manag Care Pharm201218752753922971206
   PubMed Web of Science ®Google Scholar
• ColemanCIRobertsMSSobierajDMLeeSAlamTKaurREffect of dosing frequency on chronic cardiovascular disease medication adherenceCurr Med Res Opin201228566968022429067
   PubMed Web of Science ®Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
   PubMed Web of Science ®Google Scholar
• ShoreSCareyEPTurakhiaMPAdherence to dabigatran therapy and longitudinal patient outcomes: insights from the Veterans Health AdministrationAm Heart J2014167681081724890529
   PubMed Web of Science ®Google Scholar
• Coumadin [package insert]Princeton, NJBristol-Myers Squibb2011
   Google Scholar
• AttayaSBornsteinTRonquilloNStudy of warfarin patients investigating attitudes toward therapy change (SWITCH survey)Am J Ther201219643243522198071
   PubMed Web of Science ®Google Scholar
• ElewaHFDeRemerCEKellerKGujralJJoshuaTVPatients satisfaction with warfarin and willingness to switch to dabigatran: a patient surveyJ Thromb Thrombolysis201438111512023918529
   PubMed Web of Science ®Google Scholar
• GhijbenPLancsarEZavarsekSPreferences for oral anticoagulants in atrial fibrillation: a best-best discrete choice experimentPharmacoeconomics201432111115112725027944
   PubMed Web of Science ®Google Scholar
• ColemanCIColemanSMVanderpoelJPatient satisfaction with warfarin- and non-warfarin-containing thromboprophylaxis regimens for atrial fibrillationJ Investig Med2013615878881
   PubMed Web of Science ®Google Scholar
• MonzBUConnollySJKorhonenMNoackHPooleyJAssessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-studyInt J Cardiol201316832540254723664436
   PubMed Web of Science ®Google Scholar
• CammAJAmarencoPHaasSXANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillationEur Heart J201637141145115326330425
   PubMed Web of Science ®Google Scholar
• HarringtonARArmstrongEPNolanPEJrMaloneDCCost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillationStroke20134461676168123549134
   PubMed Web of Science ®Google Scholar
• StacyZACallWBHarmannAPPetersGLRichterSKEdoxaban: a comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolismCardiol Ther2016511826935434
   PubMed Web of Science ®Google Scholar